Trial Profile
GeneVieve
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 26 May 2010
Price :
$35
*
At a glance
- Drugs Reximmune C (Primary) ; Rexin-G (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Pharmacodynamics
- Acronyms GeneVieve
- Sponsors Epeius Biotechnologies Corporation
- 24 May 2010 Trial acronym added.
- 24 May 2010 Interim results will be presented at ASCO on June 6 2010, according to a Epeius Biotechnologies Corporation media release
- 05 Jul 2006 New trial record.